XT
SKYE icon

XTX Topco’s Skye Bioscience SKYE Stock Holding History

XTX Topco’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.1K Sell
40,919
-12,121
-23% -$9.88K ﹤0.01% 3493
2025
Q4 		$39.8K Buy
+53,040
New +$77.5K ﹤0.01% 2889

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

XTX Topco's SKYE Position: Q1 2026 in Review

XTX Topco reduced its Skye Bioscience (SKYE) stake by 23% in Q1 2026, selling an estimated $9.88K and leaving 40,919 shares worth $25.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3493.

XTX Topco first reported a position in SKYE in Q4 2025 and has held it in 2 quarters since. The position peaked at $39.8K in Q4 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • XTX Topco held 40,919 shares of Skye Bioscience worth $25.1K as of Q1 2026.
  • XTX Topco sold 12,121 Skye Bioscience shares in Q1 2026, an estimated $9.88K.
  • Skye Bioscience made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3493 holding.
  • XTX Topco first reported a position in Skye Bioscience in Q4 2025 and has held it in 2 quarters since.
  • XTX Topco's Skye Bioscience position peaked at $39.8K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.